Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4606-4612.
To evaluate the relationship between body mass index (BMI) and rates of treatment tolerance and clinical outcomes in patients with locally advanced rectal cancer treated with a multimodality approach.
This study was conducted on 56 patients with histologically proven rectal adenocarcinoma, staged T3-4, and/or node-positive tumor, which underwent intensified radiochemotherapy (RT-CHT) treatment before surgery. We calculated adiposity indices and analyzed their influence on treatment tolerance and clinical outcomes.
Distribution of the 56 patients according to BMI was BMI < 25 kg/m2 (n = 19; 33.9%), BMI 25-29 kg/m2 (n = 29; 51.8%) and BMI ≥ 30 kg/m2 (n = 8; 14.3%). BMI had no significant influence on neo-adjuvant treatment-related toxicity. With a median follow-up of 23 months (range 11-47), the 2-year survival was 85.7%. We did not observe any significant difference among the three BMI categories for any of the outcomes.
This study suggested no evident links between overweight and survival in patients with locally advanced rectal carcinoma treated with neo-adjuvant RT-CHT. Overweight patients tolerate treatment as normal-weight patients.
评估体质量指数（BMI）与接受多模态治疗的局部晚期直肠癌患者的治疗耐受性和临床结局之间的关系。
本研究纳入了 56 例经组织学证实的直肠腺癌患者，分期为 T3-4 期和/或阳性淋巴结肿瘤，这些患者在手术前接受了强化放化疗（RT-CHT）治疗。我们计算了肥胖指数，并分析了它们对治疗耐受性和临床结局的影响。
根据 BMI 分布，56 例患者分为 BMI<25kg/m2（n=19；33.9%）、BMI 25-29kg/m2（n=29；51.8%）和 BMI≥30kg/m2（n=8；14.3%）。BMI 对新辅助治疗相关毒性无显著影响。中位随访 23 个月（范围 11-47），2 年生存率为 85.7%。我们未观察到 BMI 类别之间任何结局存在显著差异。
本研究提示新辅助 RT-CHT 治疗的局部晚期直肠癌患者中，超重与生存之间无明显关联。超重患者可耐受与正常体重患者相同的治疗。
